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EMPLOYMENT OPPORTUNITIES
Genomic Investigations of Benign Prostatic Hyperplasia
and Prostate Cancer.—Research positions are available
immediately for undergraduate, M.S., and/or Ph.D. stu-
dents, as well as postdoctoral and/or research associates,
to study benign prostatic hyperplasia (BPH) and prostate
cancer in my laboratory at the University of Southern
California Keck School of Medicine. Our laboratory is
currently investigating three complex phenotypes: ovar-
ian, pancreatic, and prostate cancer. Our strategy is to
dissect these diseases through a stepwise “candidate
gene” genomic approach. Our choice of candidate genes
for these two diseases was dictated by the hypothesized
involvement of particular metabolic pathways in path-
ogenesis. All three disorders—ovarian, pancreatic, and
prostate cancer—are significant public health problems
in this country. However, the molecular bases of these
three cancers are not well understood at this time. In
prostate cancer and BPH, since androgens have been
reported to regulate cell division in the prostate, we are
examining three androgen metabolic genes: HSD3B2,
HSD17B3, and SRD5A2. We have active programs in
genomics, human and molecular genetics, biochemistry,
and molecular epidemiology. We are interested in col-
leagues with enthusiasm and complementary interests to
join our multidisciplinary program. Additional infor-
mation on my laboratory can be obtained from our Web
site (http://www-scf.usc.edu/˜fctsai/homereichardt.html)
or by contacting me: Juergen Reichardt, Ph.D., Institute
for Genetic Medicine and Department of Biochemistry
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and Molecular Biology, USC Keck School of Medicine,
IGM 240, 2250 Alcazar Street, Los Angeles, CA 90089-
9075; telephone: (323) 442-1529; fax: (323) 442-2764;
e-mail: reichard@hsc.usc.edu
Postdoctoral Fellow, Medical Genetics.—The Hayward
Genetics Center at Tulane University Health Sciences Cen-
ter has an opening for a postdoctoral fellow in medical
genetics. The Human Genetics Program has an active clin-
ical genetics service with training provided at Tulane Uni-
versity Hospital and Clinic, the Medical Center of Lou-
isiana at New Orleans, and outreach clinics at several
southeast Louisiana health units. Laboratory rotations
will include both clinical laboratory and research labo-
ratory experiences in biochemical genetics, cytogenetics,
and molecular genetics. Additional research experiences
with Center faculty and associates throughout the medical
school will also be available. Requirements include com-
pletion of an Accreditation Council for Graduate Medical
Education–accredited residency, as well as the ability to
obtain medical licensure in the state of Louisiana. Tulane
University is an equal opportunity/affirmative action em-
ployer, and applications from qualified women and mi-
nority-group members are especially encouraged. Inter-
ested persons should send a curriculum vitae and the
names of three references to Jess G. Thoene, M.D., Di-
rector, Human Genetics Program, Hayward GeneticsCen-
ter SL#31, 1430 Tulane Avenue, New Orleans, LA 70112;
telephone: (504) 588-5229; e-mail: jthoene@tulane.edu
Clinical Geneticist/Cytogeneticist.—Albany Medical Cen-
ter is seeking applications to fill a full-time faculty position
as a clinical geneticist and Medical Director of the cy-
togenetics laboratory. Applicants should have a doctoral
degree, with postdoctoral training in medical cytogenetics
and clinical genetics. Board certification or eligibility for
certification by the American Board of Medical Genetics
is essential. The individual will be responsible for con-
sultation on genetics-related clinical problems in hema-
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tology, obstetrics, pediatrics, oncology, and the day-to-
day operation of the cytogenetics laboratory. Strategic
affiliations have developed with the Wadsworth Labo-
ratory (NYSDOH), the Albany College of Pharmacy, and
SUNY (Albany) to establish a broad–based clinical, ed-
ucation, and research consortium. Albany Medical Cen-
ter, a 631-bed tertiary-care center, is one of upstate New
York’s largest teaching hospitals (with 1350 full-time
faculty) and is the only academic health-sciences center
in the region. Qualified applicants should send a curric-
ulum vitae and three letters of reference to David Clark,
M.D., Chairman, Department of Pediatrics, Albany
Medical Center, Mail Code 88, 47 New Scotland Ave-
nue, Albany, NY 12208. EEO/AA Employer M/F/D. Al-
bany Medical Center actively seeks applications from
women and minorities.
Clinical Cytogeneticist/Laboratory Director.—Genetics
Associates, Inc., invites applications for the position of
laboratory director. Genetics Associates, Inc., is an in-
dependent laboratory, located in Nashville, TN, and pro-
vides service to many university-based and private hos-
pitals and physician groups in the region. The laboratory
processes 5,000 specimens annually, for prenatal (34%),
postnatal (28%), and cancer (38%) cytogenetic diag-
nosis, using state-of-the-art conventional and molecular
cytogenetic techniques. The applicant must be certified
in clinical cytogenetics by the American Board of Med-
ical Genetics, with at least 3 years of experience in a
diagnostic laboratory. In addition to directing the lab-
oratory, the selected candidate will be a course director
for pathology residents’ rotations. There is ample op-
portunity for academic interaction and research. Please
send a curriculum vitae to V. G. Dev, Ph.D., Laboratory
Director, Genetics Associates, Inc., 1916 Patterson
Street, Suite 400, Nashville, TN 37203; telephone: (615)
327-4532; e-mail: dev@geneticsassociates.com
Clinical Cytogeneticist.—American Medical Laborato-
ries (AML) invites applicants with an interest in joining
the management team of a high-volume, rapidly ex-
panding cytogenetics laboratory. AML, a regional and
national full-service referral laboratory, is located in
Northern Virginia, near Washington Dulles Interna-
tional Airport. The laboratory offers a complete array
of cytogenetic services, including tests for prenatal di-
agnostics, constitutional change, and oncology. Our spe-
cialty-test menu includes FISH analyses and diagnostic
assays for chromosome-breakage disorders. The suc-
cessful applicant’s responsibilities will include case re-
view and reporting, physician consultation, and test de-
velopment and implementation, as well as participation
in continuing education, quality-improvement, and busi-
ness-development activities. Candidates should hold a
Ph.D. degree with ABMG certification in clinical cyto-
genetics (candidates with appropriate experience who
are eligible for ABMG certification will be considered).
Certification in clinical molecular genetics is desirable.
Salary will be commensurate with experience. Fax or
mail resume with salary history to American Medical
Laboratories, Inc., Attn: Dr. Steve Schonberg, c/o
Employee Services Dept., 14225 Newbrook Drive, P.O.
Box 10841, Chantilly, VA 20153–0841; fax: (703) 802-
7088; e-mail: recruit@aml.com. AML is an equal op-
portunity/affirmative action employer.
FELLOWSHIP OPPORTUNITY
Jane Engelberg Memorial Fellowship.—The Jane En-
gelberg Memorial Fellowship (JEMF) is open to genetic
counselors who are full members, in good standing, of
the National Society of Genetic Counselors (NSGC) and
are certified in genetic counseling by the American Board
of Medical Genetics or the American Board of Genetic
Counseling. Individuals who have been granted active
candidate status by the American Board of Genetic
Counseling also are eligible to apply for a JEMF. The
ninth fellowship award, an annual $50,000 grant from
the Engelberg Foundation to the NSGC, will be awarded
for 2001–2002 to one genetic counselor (or more than
one genetic counselor who will share the award) for
study, research, writing, or exploration of new interests
to enhance present skills, develop new skills, contribute
to the body of knowledge in the field of genetic coun-
seling, or expand professional roles. Applicants must
demonstrate that the work supported by the fellowship
will produce results that (1) will be of sufficiently broad
interest to warrant professional publication and/or pre-
sentation and (2) will enrich the base of knowledge in
the professional community concerned with genetic
counseling. Applicants may elect to pursue fellowship
work, on a part-time or full-time basis, for a maximum
of 1 year. The award will be presented at the annual
NSGC Education Conference in 2001. Applications are
due May 1, 2001. A program application and guideline
booklet will be mailed in January to all NSGC full mem-
bers. For more information, contact Joan A. Scott, M.S.,
Chair, JEMF Board, c/o Gene Logic, Inc., 708 Quince
Orchard Road, Gaithersburg, MD 20878; telephone:
(240) 631-7477; fax: (301) 926-6125; e-mail: jscott@
genelogic.com
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GRANTS
Permanent Research Fund, International Rett Syndrome
Association.—Rett syndrome (RS) is a brain disorder
that appears primarily in female subjects, after a period
of normal early development, until age 6–18 mo. A pe-
riod of regression follows, during which acquired speech
and hand skills are lost and seizures, repetitive hand-
wringing or hand-washing movements, irregular
breathing, and motor-control problems develop. Indi-
viduals with RS can live to adulthood, but most never
regain the ability to use their hands or to speak. In Oc-
tober 1999, the discovery of genetic mutations in the
gene MECP2 on the X chromosome (Xq28) gave sig-
nificant insight into the cause of RS. This gene encodes
an abundant chromosomal protein (MeCP2) that acts
as a transcriptional repressor by binding to methylated
CpG base pairs throughout the genome and silencing
other genes. RS is thought to arise in great part because
of abnormal overexpression of genes improperly regu-
lated by a defective MeCP2. This is the first instance of
a human disease caused by defects in a protein with the
function of silencing other genes. Continued research is
now focused on still-unidentified genetic factors that
may contribute to RS. The International Rett Syndrome
Association (IRSA) is requesting proposals for biomed-
ical, clinical, and therapeutic research relating to RS. In
most circumstances, IRSA grants will be as much as
$40,000, with two renewals possible. For larger grants,
special permission should be obtained prior to submis-
sion. For small grants, a traditional, hypothesis-based
National Institutes of Health–type proposal to obtain
pilot data should be submitted. High-risk, high-reward
proposals are acceptable. Supplemental grants are avail-
able to enhance and extend existing NIH funded studies
by (a) adding a student, fellow, or staff member to on-
going RS studies or (b) adding an RS component to
related studies. Proposals for translational research stud-
ies, meant to enable basic research findings to move to-
ward clinical application and treatment, need not be
hypothesis-based. Submission deadlines for all grants
are January 15 and July 15. For more information, see
our Web site (http://www.rettsyndrome.org) or contact
Cheryl Dunigan, Ph.D., Scientific Director, International
Rett Syndrome Association, 9121 Piscataway Road
#2B, Clinton, MD 20735; telephone: (800) 818-RETT;
e-mail: cdunigan@rettsyndrome.org.
MEETING
International Standing Committee on Human Cyto-
genetic Nomenclature (ISCN).—New members of the
ISCN will be elected at an open meeting of cytogeneti-
cists on Wednesday, May 16, 2001, during the 10th In-
ternational Congress of Human Genetics in Vienna (see
program for venue). The Committee is elected for 5 years
and consists of five members from Europe, the United
States, and Canada and two members from the remain-
ing geographic areas. Nominations of candidates inter-
ested in serving on the Committee should be submitted
before March 15, 2001. Only candidates nominated be-
fore that date will be put on the ballot paper. Those who
are interested in voting but are unable to attend the
meeting in Vienna can request ballot papers before April
1, 2001. Nomination forms and ballot papers can be
obtained from Sheila Youings, Research Associate to
Professor P. A. Jacobs, Wessex Regional Genetics Lab-
oratory, Salisbury District Hospital, Salisbury SP2 8BJ,
Wiltshire, United Kingdom; fax: 44 (0)1772 338-095
or 331-1531; e-mail: syouings@dial.pipex.com
DNA SAMPLES
DNA Samples for Studying Autism.—A genetic resource
of DNA samples has been built at the Coriell Institute
for Medical Research, in collaboration with the clinical
services at the University of Medicine and Dentistry Rob-
ert Wood Johnson Medical School, to support the study
of autism in families in which more than one child is
affected or one child is affected and one demonstrates
another significant, related developmental disorder. An
open bank of anonymously collected material, docu-
mented by a detailed clinical diagnosis, forms the basis
of this growing database of information about the dis-
ease. Three criteria were used to assess the autistic phe-
notype: the ADI (Autism Diagnostic Interview), the
ADOS (Autism Diagnostic Observational Schedule-Ge-
neric), and the DSM-IV Diagnostic Criteria for 299.00
Autistic Disorder. All clinical interviews were conducted
face-to-face. For each donor subject tested, a represen-
tative Autistic Diagnostic Criteria Score Sheet, used to
collect data, is provided. Currently, the resource contains
20 families in which 41 individuals have been examined.
Of these individuals, 33 have a diagnosis of autistic dis-
order by two or more criteria; 28 of these satisfy all
three criteria. There are 20 affected sib pairs with a di-
agnosis of autistic disorder by two or more criteria; 9
of these pairs meet the criteria for autistic disorder by
all three criteria. Further information about this re-
source, including information on ordering, can be found
at http://locus.umdnj.edu/autism or by contact with the
Coriell Cell Repositories, Coriell Institute for Medical
Research, 401 Haddon Avenue, Camden, NJ 08103;
telephone: (800) 752-3805 in the United States, (609)
757-4848 from other countries; fax: (609) 757-9737; e-
mail: ccr@arginine.umdnj.edu
